Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Oncolytic virotherapy using replication-competent herpes simplex viruses].

Yukihiro Nishiyama1, Fumi Goshima

  • 1Department of Virology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan. ynishiya@med.nagoya-u.ac.jp

Uirusu
|November 28, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome-wide CRISPR screen for HSV-1 host factors reveals PAPSS1 contributes to heparan sulfate synthesis.

Communications biology·2022
Same author

Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma.

Molecular therapy oncolytics·2021
Same author

Antitumor activity of cyclin-dependent kinase inhibitor alsterpaullone in Epstein-Barr virus-associated lymphoproliferative disorders.

Cancer science·2019
Same author

Oncolytic activity of HF10 in head and neck squamous cell carcinomas.

Cancer gene therapy·2019
Same author

Initial Characterization of the Epstein⁻Barr Virus BSRF1 Gene Product.

Viruses·2019
Same author

The BOLF1 gene is necessary for effective Epstein-Barr viral infectivity.

Virology·2019
Same journal

[Nuclear Translocation of HTLV-1 bZIP Factor by Activation of the TGF-β/Smad Pathway: A Key Molecular Mechanism for HTLV-1 Oncogenesis].

Uirusu·2026
Same journal

[Identification of a conserved antiviral RNA editing mechanism in filamentous fungi.]

Uirusu·2026
Same journal

[Elucidation of an Intrinsic Immune Evasion Mechanism in Herpes Encephalitis].

Uirusu·2026
Same journal

[Structural analysis of Ebola virus nucleocapsid].

Uirusu·2026
Same journal

[The history of HIV].

Uirusu·2026
Same journal

[The multidisciplinary study, "Aerosol virology/Aerovirology"-A new frontier].

Uirusu·2026
See all related articles

Oncolytic virotherapy uses viruses to target cancer cells. A modified herpes simplex virus (HF10) shows promise, effectively killing tumor cells in clinical trials with minimal side effects.

Area of Science:

  • Oncolytic virotherapy
  • Virology
  • Cancer research

Context:

  • Replication-competent viruses offer a novel cancer treatment strategy.
  • Oncolytic virotherapy selectively replicates within and lyses tumor cells.
  • Past clinical trials yielded disappointing results.

Purpose:

  • To evaluate the efficacy of a novel herpes simplex virus type 1 mutant (HF10) as an oncolytic virus.
  • To assess HF10's safety and tumor-cell-killing potential in preclinical and clinical settings.

Summary:

  • A herpes simplex virus type 1 mutant, HF10, efficiently replicates in and induces cell fusion in transformed cells while being attenuated in mice.
  • HF10 exhibits deletions and insertions, lacking functional expression of UL43, UL49.5, UL55, UL56, and latency-associated transcripts.

Related Experiment Videos

  • HF10 demonstrated efficacy in animal models and induced significant tumor cell death in patients with recurrent breast and head and neck cancers via intratumoral injection.

    • Impact:

    • HF10 represents a promising oncolytic virus for treating non-central nervous system malignancies.
    • Clinical trials indicate HF10 is well-tolerated, with no significant adverse effects observed.
    • This research paves the way for advanced oncolytic virotherapy strategies.